AU2021300425A1 - Cyclic compounds for use in treating retinal degeneration - Google Patents

Cyclic compounds for use in treating retinal degeneration Download PDF

Info

Publication number
AU2021300425A1
AU2021300425A1 AU2021300425A AU2021300425A AU2021300425A1 AU 2021300425 A1 AU2021300425 A1 AU 2021300425A1 AU 2021300425 A AU2021300425 A AU 2021300425A AU 2021300425 A AU2021300425 A AU 2021300425A AU 2021300425 A1 AU2021300425 A1 AU 2021300425A1
Authority
AU
Australia
Prior art keywords
compound
subject
formula
heteroaliphatic
aromatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021300425A
Other languages
English (en)
Inventor
Yu Holly CHEN
Wenwei Huang
Zhiji LUO
Anupam Mondal
Samantha PAPAL
Anand Swaroop
Manju SWAROOP
Gregory Tawa
Wei Zheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of AU2021300425A1 publication Critical patent/AU2021300425A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021300425A 2020-07-02 2021-07-01 Cyclic compounds for use in treating retinal degeneration Pending AU2021300425A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063047858P 2020-07-02 2020-07-02
US63/047,858 2020-07-02
PCT/US2021/040157 WO2022006439A2 (en) 2020-07-02 2021-07-01 Compound embodiments for treating retinal degeneration and method embodiments of making and using the same

Publications (1)

Publication Number Publication Date
AU2021300425A1 true AU2021300425A1 (en) 2023-02-02

Family

ID=77227100

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021300425A Pending AU2021300425A1 (en) 2020-07-02 2021-07-01 Cyclic compounds for use in treating retinal degeneration

Country Status (6)

Country Link
US (1) US20230301984A1 (https=)
EP (1) EP4175636A2 (https=)
JP (1) JP2023532134A (https=)
AU (1) AU2021300425A1 (https=)
CA (1) CA3186586A1 (https=)
WO (1) WO2022006439A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4705277A1 (en) * 2023-04-27 2026-03-11 Kiora Pharmaceuticals Pty Ltd Method of treating vision loss in a human subject with photoreactive compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0489108B1 (en) * 1989-08-21 1996-03-13 Beth Israel Hospital Association Use of spiperone derivatives for immunosuppression
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5725493A (en) 1994-12-12 1998-03-10 Avery; Robert Logan Intravitreal medicine delivery
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
CA2383499C (en) 1999-10-21 2009-11-24 Alcon Universal Ltd. Drug delivery device
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
CN101534826A (zh) * 2006-04-14 2009-09-16 普拉纳生物技术有限公司 治疗与年龄相关的黄斑变性（amd）的方法
WO2009035534A2 (en) * 2007-09-07 2009-03-19 The Cleveland Clinic Foundation Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
WO2009089399A2 (en) * 2008-01-10 2009-07-16 Bausch & Lomb Incorporated Compositions comprising toll-like receptor or coreceptor antagonists and methods for ocular neuroprotection
US10258613B2 (en) * 2014-02-05 2019-04-16 The Board Of Regents Of The University Of Oklahoma Compositions for treating retinal degeneration and methods of production and use thereof
US11406709B2 (en) * 2014-09-15 2022-08-09 Trustees Of Boston University Therapeutic and research application of PDCL3
US10322087B2 (en) * 2015-03-16 2019-06-18 Mireca Medicines Gmbh Targeted liposomal delivery of cGMP analogues
US20210338770A1 (en) * 2018-10-15 2021-11-04 Osaka University Medicament for improving or preventing symptoms relating to retina and/or light reception and method for screening for substance capable of improving or preventing symptoms relating to retina and/or light reception

Also Published As

Publication number Publication date
US20230301984A1 (en) 2023-09-28
WO2022006439A3 (en) 2022-02-10
EP4175636A2 (en) 2023-05-10
CA3186586A1 (en) 2022-01-06
WO2022006439A2 (en) 2022-01-06
JP2023532134A (ja) 2023-07-26

Similar Documents

Publication Publication Date Title
JP5911470B2 (ja) アミロイドまたはアミロイド様タンパク質と関連する疾患を治療するための新規化合物
JP7757036B2 (ja) Ｋｖ７チャネル活性化剤の構成および使用方法
KR102726637B1 (ko) 6-아미노이소퀴놀린의 일가-(산) 염 및 이의 용도
KR102733897B1 (ko) Cftr 조절제 및 이의 사용방법
JP2024144702A (ja) 網膜疾患の治療のための眼内または経口投与用医薬組成物
JP2009196973A (ja) キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含有する後眼部疾患の予防又は治療剤
JP7664861B2 (ja) 眼障害の治療のための化合物
US20230301984A1 (en) Cyclic compounds for use in treating retinal degeneration
CN111315369A (zh) 用于治疗眼部病症和皮肤疾病的化合物、组合物和方法
JP2012006918A (ja) イソキノリンスルホニル誘導体を有効成分として含有する網脈絡膜変性疾患の予防または治療剤
US20230089949A1 (en) Small molecules for treating age-related retinal diseases
CN1225093A (zh) 苯并[g]喹啉衍生物
JP2003026677A (ja) ３−フェニル−３，７−ジアザビシクロ［３，３，１］ノナン−化合物、これを含有する医薬品、その使用及びその製法
CN101198325A (zh) 用于治疗高眼压的眼用组合物
JP2026065369A (ja) フックス角膜内皮ジストロフィの予防用または治療用医薬
WO2024229096A1 (en) Modified forms of ambroxol for therapeutic use
WO2023100918A1 (ja) 新規ニコチンアミド化合物及びその用途
CA3235692A1 (en) Modified forms of ambroxol for therapeutic use
WO2021208850A1 (zh) 硝基咪唑类衍生物及其制备方法和用途
CN1938262A (zh) 季铵化合物、其制备方法、脑血管障碍治疗剂及心脏疾病治疗剂
KR20110126132A (ko) 4,6-디클로로-1η-인돌-2-카르복실산 유도체 또는 이의 염을 유효 성분으로서 함유하는 시신경 장애의 예방 또는 치료제